Drug Interaction Report
1 drug interaction and 10 additional warnings found for the following 2 drugs:
- capivasertib
- treosulfan
Drug interactions
Moderate drug interactions
Moderate:treosulfan capivasertib
Applies to: treosulfan, capivasertib
Treosulfan may increase the blood levels and effects of capivasertib.
Contact your doctor if your condition changes during treatment with these medications. You may need a dose adjustment or more frequent monitoring to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:Food/Lifestyle capivasertib
Applies to: capivasertib
Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be avoided during treatment with capivasertib as they may increase the blood levels of capivasertib.
This may increase the risk of side effects such as:
- high blood sugar levels
- diarrhea
- skin reactions
- nausea
- vomiting
- tiredness
- changes in certain blood tests
Talk to your doctor if you have any questions or concerns.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
9 potential interactionsApplies to: 7 conditions, including Type 2 Diabetes, Seizures, Diabetes, Type 1, Diabetes Mellitus, and Liver Disease.
Diabetes, Type 1
Moderate:capivasertib
Capivasertib has a moderate potential interaction with Diabetes, Type 1.
Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.
Diabetes Mellitus
Moderate:capivasertib
Capivasertib has a moderate potential interaction with Diabetes Mellitus.
Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.
Diabetic Ketoacidosis
Moderate:capivasertib
Capivasertib has a moderate potential interaction with Diabetic Ketoacidosis.
Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.
Liver Disease
Moderate:capivasertib
Capivasertib has a moderate potential interaction with Liver Disease.
Capivasertib has not been studied in patients with severe hepatic impairment (bilirubin greater than 3 times ULN and any AST). In patients with moderate hepatic impairment (bilirubin greater than 1.5 to 3 times ULN and any AST), additional monitoring for adverse side effects is recommended due to the potential for increased exposure. No dose adjustment is recommended in patients with mild hepatic impairment.
Moderate:treosulfan
Treosulfan has a moderate potential interaction with Liver Disease.
Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.
Renal Dysfunction
Moderate:capivasertib
Capivasertib has a moderate potential interaction with Renal Dysfunction.
Capivasertib has not been studied in patients with severe renal dysfunction (CrCl 15 to 29 mL/min). No dose adjustment is recommended in patients with mild to moderate renal dysfunction (CrCl 30 to 89 mL/min).
Moderate:treosulfan
Treosulfan has a moderate potential interaction with Renal Dysfunction.
Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.
Seizures
Moderate:treosulfan
Treosulfan has a moderate potential interaction with Seizures.
There have been reports of seizures in patients following treatment with treosulfan. Patients should be monitored for signs of neurological adverse reactions, and clonazepam prophylaxis may be considered for patients at higher risk for seizures, including infants.
Type 2 Diabetes
Moderate:capivasertib
Capivasertib has a moderate potential interaction with Type 2 Diabetes.
Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, has occurred in patients treated with capivasertib. The safety of capivasertib in patients with Type 1 diabetes or with diabetes requiring insulin has not been established; these patients were excluded from clinical studies. Fasting blood glucose and hemoglobin A1C should be evaluated and optimized before starting treatment. Regular monitoring of fasting blood glucose as recommended by the manufacturer should be performed during treatment with capivasertib. Consider consultation with a specialist in the treatment of hyperglycemia and initiation of fasting glucose monitoring at home for patients who have risk factors for or who experience hyperglycemia. If hyperglycemia occurs during treatment, the dose of capivasertib may need to be withheld or reduced, or treatment permanently discontinued based on severity or if ketoacidosis is confirmed.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.